Last reviewed · How we verify

bioRASI, LLC — Portfolio Competitive Intelligence Brief

bioRASI, LLC pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Reference: Metronidazole Gel 1% Reference: Metronidazole Gel 1% phase 3 Nitroimidazole antibiotic Bacterial and protozoal DNA Infectious Disease / Dermatology
Test: Metronidazole Gel 1% Test: Metronidazole Gel 1% phase 3 nitroimidazole antibiotic Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Appili Therapeutics Inc. · 1 shared drug class
  2. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  3. Balmoral Medical company · 1 shared drug class
  4. Dongfang Hospital Beijing University of Chinese Medicine · 1 shared drug class
  5. Johns Hopkins Bloomberg School of Public Health · 1 shared drug class
  6. LEO Pharma · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for bioRASI, LLC:

Cite this brief

Drug Landscape (2026). bioRASI, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biorasi-llc. Accessed 2026-05-16.

Related